- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00865878
ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients
A Randomized, Evaluator-Blinded, Parallel Group Comparison of PDT With Levulan Topical Solution + Blue Light vs Levulan Topical Solution Vehicle + Blue Light for the Treatment of AK and Reduction of New NMSC in Organ Transplant Recipients
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This is a Phase II multicenter, randomized, evaluator-blinded, vehicle-controlled, parallel group study of photodynamic therapy in organ transplant recipient subjects for treatment of AK and the reduction of new NMSC.
Subjects will be randomized to one of the following two treatment groups (1:1) to receive topical Levulan® Kerastick® containing 20% aminolevulinic acid HCL (ALA, active study drug) or the Kerastick® containing vehicle ingredients only (VEH).
- Group 1 will have ALA applied to the entire scalp OR both forearms 90 +/- 30 minutes prior to BLUE light treatment for 16 minutes 40 seconds
- Group 2 will have VEH applied to the entire scalp OR both forearms 90 +/- 30 minutes prior to BLUE light treatment for 16 minutes 40 seconds
Treatment Area (scalp or both forearms) must have had at least 2 NMSC in the past 12 months, and must include a continuous 25 cm2 Target Area containing a minimum of 3 AKs, to be eligible for treatment
Each subject may receive up to nine treatments. The initial four (4) ALA-PDT/VEH-PDT treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks. Post-treatment follow-up visit will be scheduled to occur 4 weeks after the subject's final PDT.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
California
-
Irvine, California, Forente stater, 92697
- University of California, Irvine
-
San Francisco, California, Forente stater, 94115
- University of California, San Francisco
-
-
Florida
-
Miami, Florida, Forente stater, 33136
- University of Miami
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02111
- Tufts Medical Center
-
-
New York
-
New York, New York, Forente stater, 10029
- The Mount Sinai Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19111
- Fox Chase Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37204
- Vanderbilt University Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Subject is male or non-pregnant female organ transplant (kidney, liver, pancreas, lungs, heart or combinations thereof) recipient outpatient 18 years of age or older. Females must be post-menopausal, surgically sterile or using a medically acceptable form of birth control, with a negative urine pregnancy test at the Baseline visit.
- Subject has provided written and verbal informed consent.
- Subject has at least 3 actinic keratosis lesions in a continuous 25 cm2 Target Area within the selected anatomic treatment site (scalp or forearm).
- Subject has a history of a minimum of 2 NMSC on the treatment area of interest (scalp OR both forearms) in the past 12 months
- Subject is currently receiving standard active pharmacologic immunosuppression
- Subject is willing to comply with study instructions and return to the clinic for required visits.
- Subject has Fitzpatrick skin type I-IV.
Exclusion Criteria:
- Subject is pregnant, lactating, or is planning to become pregnant during the study.
- Subject has a history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis.
- Subject has any skin pathology or condition, in the investigator's opinion, that could interfere with the evaluation of the test product or requires the use of interfering topical or systemic therapy.
- Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
- Subject is currently enrolled in an investigational drug (including experimental immunosuppressive agents containing new chemical entities) or device study. Novel combinations of and alternative dosing regimens of approved immunosuppressive agents are allowed.
- Subject has received an investigational drug (including experimental immunosuppressive agents containing new chemical entities) or been treated with an investigational device within 30 days prior to the initiation of treatment (baseline). Novel combinations of and alternative dosing regimens of approved immunosuppressive agents are allowed.
- Subject is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function.
- Subject may be unreliable for the study including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits.
- Subject has a known sensitivity to one or more of the vehicle components (ethyl alcohol, isopropyl alcohol, laureth 4, polyethylene glycol).
- Subject has active recurrent herpes simplex labialis infection in the treatment area with an outbreak within the last 12 months and will not be placed on antiviral prophylaxis as specified in the protocol.
Subject has used any of the following topical preparations on the selected Treatment Area (scalp OR both forearms):
- Keratolytics including urea (greater than 5%), alpha hydroxyacids [e.g. glycolic acid, lactic acid, etc. greater than 5%], salicylic acid (greater than 2%) within 2 days of initiation of treatment.
- 5-FU, cryotherapy, diclofenac, imiquimod or other treatments for AK within 2 weeks of initiation of treatment
- Retinoids, including tazarotene, adapalene, tretinoin, retinol, within 4 weeks of the initiation of treatment.
- Microdermabrasion, laser ablative treatments, ALA-PDT or chemical peels within 8 weeks of the initiation of treatment.
- Two or more ALA PDT treatments in the past 6 months
- Subject has used systemic retinoid therapy within 6 months of the initiation of treatment.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: 1
Topical Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA) will be applied to the entire scalp OR both forearms 90 +/- 30 minutes prior to blue light treatment for 16 minutes and 40 seconds.
|
20% aminolevulinic acid HCL (ALA) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light.
Up to nine (9) ALA-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
Andre navn:
|
Placebo komparator: 2
Kerastick containing vehicle ingredients only (VEH) will be applied to the entire scalp OR both forearms 90 +/- 30 minutes prior to blue light treatment for 16 minutes 40 seconds.
|
Vehicle ingredients only (VEH) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light.
Up to nine (9) VEH-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Number of Skin Cancers within the Treatment Area
Tidsramme: entire study
|
entire study
|
AK Lesions Counts/Surface Area
Tidsramme: Visits 1,3,5,7,9,11,13,15,17,19
|
Visits 1,3,5,7,9,11,13,15,17,19
|
Investigator Global Assessment
Tidsramme: Visits 1,3,5,7,9,11,13,15,17,19
|
Visits 1,3,5,7,9,11,13,15,17,19
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Subject Acceptability of Treatment
Tidsramme: End of Study
|
End of Study
|
Tolerability Parameters
Tidsramme: Each Visit
|
Each Visit
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Stuart L Marcus, MD, PhD, Sponsor GmbH
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- DUSA-CP0104
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Neoplasmer i huden
-
Alma LasersTilbaketrukket
-
Guangzhou First People's HospitalFullført
-
Syneron MedicalFullførtSkin Resurfacing | RynkereduksjonForente stater, Canada
-
MolecuLight Inc.UkjentSkin Graft (Allograft) (Autograft) FeilStorbritannia
-
Centre Hospitalier le MansRekruttering
-
University Hospital "Sestre Milosrdnice"Har ikke rekruttert ennåNeseplastikk | Nasal Skin-myk vevskonvolutt metabolisme | Melkesyre | Autolog bruskpode
-
University of CatanzaroUniversity of Roma La SapienzaUkjent
-
The First Affiliated Hospital of Dalian Medical...UkjentSår og skader | Traume | Brudd, åpen | Skin ExpanderKina
-
Integrative Skin Science and ResearchBurt's Bees Inc.RekrutteringKviser | Skin MicroboimeForente stater
-
PT. Daewoong InfionEquilab InternationalFullførtHudtransplantasjonsarr | Split-Thickness Skin Graft (STSG)Indonesia
Kliniske studier på Aminolevulinic Acid
-
Ultragenyx Pharmaceutical IncFullførtHereditary Inclusion Body Myopati (HIBM)Forente stater
-
National University of Ireland, Galway, IrelandStanley Medical Research InstituteFullførtBipolar depresjonIrland
-
University of California, Los AngelesFullførtGlukoseintoleranse | Overvektige | Pre-diabetesForente stater
-
Becton, Dickinson and CompanyAktiv, ikke rekrutterende
-
Hadassah Medical OrganizationFullført
-
BayerFullførtKontrastmedierForente stater, Tyskland, Italia, Korea, Republikken, Østerrike, Thailand, Australia, Spania, Storbritannia
-
Ultragenyx Pharmaceutical IncAvsluttetArvelig inkluderingskroppsmyopati | GNE Myopati | Inkluderingskroppsmyopati 2 | Distal myopati med kantede vakuoler | Distal myopati, Nonaka Type | Quadriceps sparende myopatiCanada, Forente stater, Bulgaria
-
McMaster UniversityAjinomoto USA, INC.FullførtPsykologiske fenomener: Sentral tretthetCanada
-
Ultragenyx Pharmaceutical IncAvsluttetArvelig inkluderingskroppsmyopati | GNE Myopati | Distal myopati med kantede vakuoler | Distal myopati, Nonaka Type | Quadriceps sparende myopatiForente stater, Canada, Storbritannia, Israel, Italia, Bulgaria, Frankrike
-
Assistance Publique - Hôpitaux de ParisLaboratoires Vivacy; INTERmedic; Laboratoires IPRAD PHARMARekruttering